Q3 Loss Nearly Doubles and Misses Estimates, but Weight-Maintenance Data Lifts Shares 6%
VKTX is trading near its 52-week low of $23.82 (14% above the low).
Summary
Viking posted a Q3 loss of $1.55 per share against $1.07 expected, with the net loss at $183.2M versus $90.8M a year ago as R&D jumped to $166.8M from $90M and G&A to $20.3M from $8.6M. The miss is being offset by pipeline news: patients who stepped down from weekly VK2735 injections kept 83% to 97% of their weight loss on every-other-week dosing and 82% to 90% on monthly dosing, versus 61% for placebo. Viking also began the SUNRISE Phase 3 program for an oral VK2735 tablet, two trials of 560 patients each dosed for 68 weeks, aiming to be first to market with an oral drug hitting both GLP-1 and GIP. The $960M cash balance funds operations through at least December 31, 2027, covering the late-stage trials and commercial build-out. Shares are up 6.19% at $26.93, still near the $23.82 52-week low. The injectable VANQUISH-1 and VANQUISH-2 Phase 3 trials, roughly 4,500 and 1,000 patients, are expected to complete in 2027.
At the time of this announcement, VKTX was trading at $27.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $23.82 to $43.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.